Technical Analysis for ARCT - Arcturus Therapeutics Ltd.

Grade Last Price % Change Price Change
F 16.19 -6.36% -1.10
ARCT closed down 6.36 percent on Friday, February 7, 2025, on 1.13 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
50 DMA Support Bullish -6.36%
Bollinger Band Squeeze Range Contraction -6.36%
BB Squeeze Started Range Contraction -6.36%
Inside Day Range Contraction -6.36%
Crossed Above 20 DMA Bullish -9.70%
Crossed Above 50 DMA Bullish -9.70%

   Recent Intraday Alerts

Alert Time
Fell Below Lower Bollinger Band about 15 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago
Down 2 % about 18 hours ago
Fell Below 10 DMA about 18 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arcturus Therapeutics Ltd. Description

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Health Sciences Pharmacology Euphoriants Amphetamine Cognitive Disorders Adhd Glutamate Tablet

Is ARCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 45.0
52 Week Low 14.3
Average Volume 392,618
200-Day Moving Average 22.16
50-Day Moving Average 17.20
20-Day Moving Average 16.87
10-Day Moving Average 16.74
Average True Range 1.37
RSI (14) 45.36
ADX 9.15
+DI 22.78
-DI 21.75
Chandelier Exit (Long, 3 ATRs) 17.14
Chandelier Exit (Short, 3 ATRs) 19.46
Upper Bollinger Bands 18.01
Lower Bollinger Band 15.74
Percent B (%b) 0.2
BandWidth 13.43
MACD Line -0.17
MACD Signal Line -0.17
MACD Histogram -0.0002
Fundamentals Value
Market Cap 438.55 Million
Num Shares 27.1 Million
EPS -2.33
Price-to-Earnings (P/E) Ratio -6.95
Price-to-Sales 2.73
Price-to-Book 1.79
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.46
Resistance 3 (R3) 18.63 18.06 18.08
Resistance 2 (R2) 18.06 17.48 17.97 17.95
Resistance 1 (R1) 17.12 17.12 16.84 16.95 17.83
Pivot Point 16.55 16.55 16.40 16.46 16.55
Support 1 (S1) 15.61 15.97 15.33 15.44 14.55
Support 2 (S2) 15.04 15.61 14.95 14.43
Support 3 (S3) 14.10 15.04 14.30
Support 4 (S4) 13.93